BMRN (BioMarin Corp) Multiplikator Forward P/S

Lambang korporat lan logo BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical (BMRN) maintains a monopoly on lifelong therapies for orphan diseases, ensuring stable demand that drives the forward P/S trend. The 3.00 level is recording fresh values as management balances shareholder profit demands against trial risks. Meanwhile, the expansion of the drug Voxzogo is creating strong momentum, offsetting the stagnation of legacy product lines and establishing new growth catalysts.

BioMarin - Multiplikator Forward P/S BMRN (periode 04.07.2022 - 13.11.2026)

Ringkesan rincian data analitis BioMarin Corp (BMRN)

- rega pasar lan target rega analis:
Bagan rega BioMarin|BMRN - Bagan tingkat prakiraan
- indikator valuasi pasar bisnis:
Kapitalisasi pasar BioMarin Corp|BMRN - Nilai Dipunlarasaken Utang lan Kas
- statistik nilai buku emiten:
Nilai Buku saben Saham BioMarin|BMRN - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku biomarin.com|BMRN - Nilai Agregat Aset
- informasi babagan utang lan solvabilitas:
Utang marang Ekuitas BioMarin Pharmaceutical|BMRN - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal BioMarin Pharmaceutical|BMRN - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku BioMarin Corp|BMRN - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan BioMarin|Likuiditas cepet biomarin.com
- rincian asil keuangan lan kelipatan valuasi:
BMRN - Penghasilan resik perusahaan|Bathi sing dikarepake BioMarin Pharmaceutical|BMRN - Koefisien rega marang bathi|Pangali Forward P/E BioMarin Pharma|BMRN - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan BioMarin Corp|BMRN - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) BioMarin|BMRN - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan biomarin.com|BMRN - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep BioMarin Pharmaceutical
- data total pendapatan lan volume dodolan:
BMRN - Pendapatan dodolan perusahaan|Prakiraan pendapatan perusahaan BioMarin|BMRN - Rasio rega marang dodolan|Multiplikator Forward P/S BioMarin Corp
Analisis fundamental perusahaan:BioMarin BMRN
Produk asli BioMarin Corp

The forward P/S reflects the market value of BioMarin Pharmaceutical (BMRN) relative to projected annual revenue, allowing for an assessment of the premium investors are paying for future growth. For a company with a costly cold chain supply for orphan drugs, this ratio accounts for the impact of high logistics costs on final margins. By analyzing the forward price-to-sales ratio, one can determine a fair business valuation and minimize the risks of excessive capital concentration.

Karo sapa BioMarin Pharmaceutical saingan

Rasio rega marang prakiraan pendapatan Vertex VRTX|ALNY (Alnylam Pharmaceuticals, Inc.) - Rega mangsa ngarep marang pendapatan|Insmed Inc - Multiplikator Forward P/S|Rega forward marang dodolan UTHR (United Therapeutics Inc.)|BBIO: Multiplikator Forward P/S|BGM Group (BGM) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Cogent Biosciences, Inc.|XERS: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Keros Pharma (KROS)|Multiplikator forward rega marang pendapatan Arcturus Corp ARCT|Multiplikator Forward P/S ETON (Eton Pharmaceuticals)|Multiplikator Forward P/S kamada.com KMDA|Fulcrum Therapeutics, Inc. - Multiplikator Forward P/S|ABEO: Rasio rega marang prakiraan pendapatan|MREO: Multiplikator Forward P/S|PLX - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Pliant Therapeutics Inc|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep appliedtherapeutics.com APLT|Rasio rega marang prakiraan pendapatan Rein Therapeutics (RNTX)|Multiplikator forward rega marang pendapatan gelteq.com GELS|Multiplikator Forward P/S AYTU (Aytu BioPharma)|Multiplikator Forward P/S Chemomab Therapeutics Ltd CMMB|SRXH - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan PLRZ (Polyrizon Ltd)|AEZS: Multiplikator Forward P/S|CYTH - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Inozyme Pharma Inc.|Kapitalisasi marang prakiraan pendapatan RPHM (Reneo Pharmaceuticals, Inc)|Multiplikator forward rega marang pendapatan CSCI (COSCIENS Biopharma Inc.)